Perceptive Advisors BLLN Position
ActivePerceptive Advisors initiated a new position in BillionToOne, Inc. (BLLN) in Q4 2025, holding $6.0M worth of shares across 72,812 shares.
1 other tracked fund also holds BLLN.
There is an upcoming Phase 2 readout for 5-Fluorouracil in 1628 days (Sep 30, 2030), making the timing of Perceptive's position particularly relevant.
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Full company profile →Short Interest
7.7%
3.7 days to cover
Frequently Asked Questions
Does Perceptive Advisors own BLLN?
Yes. As of Q4 2025, Perceptive Advisors holds 72,812 shares of BillionToOne, Inc. (BLLN) valued at $6.0M. This data comes from their SEC 13F filing.
How many hedge funds own BLLN?
2 specialist biotech hedge funds currently hold BLLN, including Deep Track Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy BLLN?
Perceptive Advisors's position in BLLN was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's BLLN position increasing or decreasing?
Perceptive Advisors initiated a new position in BLLN in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BLLNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →